List of Excipients in Branded Drug LIALDA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	LIALDA	mesalamine	54092-476	CARBOXYMETHYLCELLULOSE SODIUM
Takeda Pharmaceuticals America Inc	LIALDA	mesalamine	54092-476	CARNAUBA WAX
Takeda Pharmaceuticals America Inc	LIALDA	mesalamine	54092-476	FERRIC OXIDE RED
Takeda Pharmaceuticals America Inc	LIALDA	mesalamine	54092-476	MAGNESIUM STEARATE

LIALDA Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

LIALDA is a mesalamine delayed-release tablet built around Cosmo Pharmaceuticals' Multi Matrix System, or MMX, technology. Its commercial value depends less on mesalamine itself, which is widely available, than on reproducible excipient performance, pH-dependent release, tablet size, coating robustness, and regulatory equivalence. The strongest opportunities are generic or authorized-generic supply, lactose-free reformulation, coating and polymer sourcing, manufacturing process optimization, and lower-cost high-dose regimens.

What is LIALDA and how does its formulation work?

LIALDA contains mesalamine, also known as 5-aminosalicylic acid, in 1.2 g delayed-release tablets. The FDA-approved product uses a multimatrix tablet designed to release mesalamine in the colon after passing through the stomach and small intestine.

The product is approved for:

• Induction of remission in adults and pediatric patients aged six years and older with mildly to moderately active ulcerative colitis.
• Maintenance of remission in adults with ulcerative colitis.

The labeled adult induction dose is generally 2.4 g to 4.8 g once daily. Maintenance dosing is generally 2.4 g once daily. This creates a treatment burden of two to four large tablets per day at common doses.[1]

The formulation uses a hydrophilic and lipophilic matrix with a pH-dependent enteric coating. The design combines matrix swelling, diffusion control, and delayed coating dissolution. The commercial objective is colonic delivery rather than rapid mesalamine release in the upper gastrointestinal tract.

What excipients are used in LIALDA tablets?

The FDA labeling identifies the following inactive ingredients.

Formulation component	Reported excipients	Commercial function
Tablet matrix and core	Carboxymethylcellulose sodium	Hydrophilic matrix former and viscosity modifier
Tablet matrix and core	Glyceryl behenate	Lipophilic matrix former and release-control excipient
Tablet matrix and core	Lactose monohydrate	Diluent and compression aid
Tablet core	Magnesium stearate	Lubricant
Tablet core	Colloidal anhydrous silica	Glidant and flow aid
Tablet core	Sodium starch glycolate	Disintegrant and matrix-performance modifier
Film coating	Methacrylic acid copolymer Type A	Enteric polymer
Film coating	Methacrylic acid copolymer Type B	Enteric polymer with complementary dissolution profile
Film coating	Triethyl citrate	Plasticizer
Film coating	Hypromellose	Film-forming polymer
Film coating	Polyethylene glycol	Plasticizer and coating-process aid
Film coating	Talc	Anti-tacking and coating aid
Film coating	Titanium dioxide	Opacifier
Film coating	Ferric oxide yellow	Colorant

The exact source, grade, particle size, substitution level, viscosity, and compendial status of each excipient can affect performance. A generic manufacturer cannot assume that a nominally identical ingredient will produce an equivalent product.

The most formulation-critical materials are likely the methacrylic acid copolymers, glyceryl behenate, carboxymethylcellulose sodium, sodium starch glycolate, and coating plasticizers. Changes in polymer grade or matrix morphology can alter dissolution at multiple pH stages.

Which excipients are strategically important for generic LIALDA?

Enteric polymers

The Type A and Type B methacrylic acid copolymers are central to the release mechanism. Their acid dissolution thresholds differ, allowing the coating to remain intact in the stomach and dissolve as intestinal pH rises.

Commercial risks include:

• Polymer variability between suppliers.
• Differences in neutralization behavior and particle size.
• Coating defects caused by poor dispersion or inadequate plasticization.
• Delayed or incomplete release in higher-pH dissolution media.
• Supply concentration among major pharmaceutical polymer producers.

A supplier that can provide validated, compendial polymer grades with strong lot-to-lot consistency has a direct opportunity in LIALDA-equivalent manufacturing.

Glyceryl behenate

Glyceryl behenate provides the lipophilic component of the matrix. Its fatty-acid composition, melting behavior, and particle-size distribution can influence tablet hardness, erosion, and mesalamine diffusion.

Substitution with another lipid excipient may be technically possible but would increase formulation-development and bioequivalence risk. The opportunity is strongest for controlled sourcing, particle engineering, and process optimization rather than simple ingredient replacement.

Carboxymethylcellulose sodium

Carboxymethylcellulose sodium contributes to matrix hydration and viscosity. Degree of substitution and viscosity grade are important. A change in grade can modify swelling, water penetration, tablet erosion, and dissolution.

Manufacturers can create value through:

• Narrow-viscosity excipient grades.
• Improved lot consistency.
• Reduced microbial burden.
• Better compatibility with high-shear wet granulation or direct compression.
• Dual sourcing supported by comparative dissolution data.

Sodium starch glycolate

Sodium starch glycolate is typically associated with rapid swelling and disintegration. In an MMX tablet, its role must be balanced against prolonged matrix control. Excessive swelling can produce premature drug release, while insufficient swelling can cause incomplete release.

This excipient is a potential source of formulation differentiation because particle morphology, substitution level, and swelling capacity can affect the full dissolution profile.

How does LIALDA compare with other mesalamine products?

Product	Active ingredient	Dosage form	Release strategy	Commercial implication
LIALDA	Mesalamine	1.2 g delayed-release tablet	MMX matrix with enteric coating	High tablet strength and once-daily positioning
Asacol HD	Mesalamine	Delayed-release tablet	pH-dependent coating	Competes on established mesalamine use
Apriso	Mesalamine	Extended-release capsule	Granule-based release system	Lower unit dose but different administration profile
Pentasa	Mesalamine	Controlled-release capsule	Ethylcellulose-coated microgranules	More distributed release through the gastrointestinal tract
Delzicol	Mesalamine	Delayed-release capsule	Encapsulated delayed-release dosage form	Capsule-based alternative
Balsalazide	Balsalazide disodium	Capsule	Colonic conversion to mesalamine	Different prodrug mechanism

LIALDA's competitive advantage has historically been its high-strength, once-daily tablet. Its disadvantages include large tablet size, multiple-tablet dosing at higher induction doses, and the technical complexity of reproducing the MMX release profile.

What commercial opportunities exist in LIALDA excipients?

Generic and authorized-generic supply

The primary opportunity is supplying excipients to ANDA manufacturers of mesalamine delayed-release tablets. Mesalamine is a small molecule, so biosimilar development is not relevant. Competition occurs through the abbreviated new drug application pathway, subject to pharmaceutical equivalence and bioequivalence requirements.[2]

Excipient suppliers can target:

• Methacrylic acid copolymer Type A and Type B.
• Pharmaceutical-grade glyceryl behenate.
• High-consistency carboxymethylcellulose sodium.
• Sodium starch glycolate with controlled swelling.
• Triethyl citrate and coating-process additives.
• Colorant and titanium dioxide systems.
• Finished coating premixes for enteric tablets.

A supplier offering a complete coating system can reduce customer qualification time compared with selling individual ingredients.

Lactose-free LIALDA-equivalent formulations

LIALDA contains lactose monohydrate. A lactose-free formulation could address patients with lactose intolerance, dietary preferences, or excipient sensitivities. The opportunity is technically credible but not automatically straightforward.

Replacing lactose can change:

• Tablet density.
• Compression behavior.
• Porosity.
• Moisture uptake.
• Matrix hydration.
• Coating adhesion.
• Dissolution and bioequivalence.

Potential substitutes include microcrystalline cellulose, mannitol, dibasic calcium phosphate, and other direct-compression fillers. Each substitution would require comparative dissolution and bioequivalence work. A lactose-free product could be positioned as a differentiated generic if the regulatory pathway and labeling support the claim.

Smaller or easier-to-swallow tablets

The 1.2 g strength permits once-daily positioning but creates a large tablet. Commercial development could focus on:

• Higher drug loading.
• Bilayer or multilayer compression.
• Multiparticulate capsules.
• Mini-tablet systems.
• Alternative strength combinations.
• Improved tablet geometry and surface coating.

The main limitation is that a new dosage form may require a different regulatory strategy than a conventional ANDA product. A manufacturer seeking a 505(b)(2) pathway could pursue a modified dosage form, but development cost and clinical requirements would increase.

Excipient supply-chain resilience

LIALDA-equivalent products depend on coordinated sourcing of matrix and coating materials. A dual-source strategy can reduce risks from:

• Polymer production interruptions.
• Changes in compendial specifications.
• Colorant restrictions.
• International shipping disruption.
• Supplier changes in manufacturing site or raw-material origin.
• Regulatory changes affecting titanium dioxide or other coating ingredients.

The most valuable suppliers will provide regulatory support packages, change-control commitments, elemental impurity data, residual-solvent data, and dissolution comparability data.

What formulation patents protect LIALDA?

LIALDA's protection has historically centered on the MMX controlled-release architecture, tablet composition, manufacturing methods, and mesalamine delivery profile. The formulation estate is more relevant than a simple active-ingredient patent because mesalamine has been off patent for decades.

Patent analysis should distinguish among:

1. Composition-of-matter claims covering the matrix and coating combination.
2. Pharmaceutical-composition claims covering mesalamine loading and excipient ratios.
3. Method-of-use claims covering ulcerative-colitis treatment.
4. Manufacturing claims covering granulation, compression, coating, and release control.
5. Regulatory exclusivity and patent listings in the FDA Orange Book.

The FDA Orange Book, Drugs@FDA records, and federal court dockets are the controlling sources for current listed patents, expiration dates, and litigation status.[2,3] Patent expiration alone does not determine generic entry. Paragraph IV certifications, 30-month stays, pediatric exclusivity, settlements, and product-specific regulatory requirements can alter the timing.

When did LIALDA lose exclusivity and what generic-entry risks remain?

LIALDA has faced generic competition after the expiry or settlement of key formulation protections. Generic entry risk is now primarily commercial and technical rather than active-ingredient related.

Risk category	Impact on LIALDA
Paragraph IV challenge	Can accelerate litigation and create an earlier generic-entry date
Formulation non-infringement	Generic manufacturers may design around specific excipient or process claims
Dissolution failure	The main technical risk for ANDA applicants
Tablet-size burden	Creates an opening for alternative dosage forms
Supply concentration	Can increase cost and delay generic launches
Physician inertia	Can slow substitution despite regulatory approval
Formulary contracting	Can shift volume rapidly toward lower-cost products

A generic applicant must reproduce the relevant release characteristics across pH conditions and demonstrate bioequivalence under FDA requirements. For a complex delayed-release matrix, formulation similarity and dissolution control can be more difficult than for an immediate-release tablet.

What is the FDA regulatory status of LIALDA?

LIALDA is an FDA-approved prescription mesalamine product. The reference product is regulated as a small-molecule drug, and generic competitors use the ANDA pathway rather than a biosimilar pathway.[1,2]

The critical regulatory issues are:

• Pharmaceutical equivalence to the reference listed drug.
• Matching strength and dosage form.
• Delayed-release performance.
• Comparative dissolution.
• Bioequivalence.
• Stability under long-term and accelerated conditions.
• Excipient justification and manufacturing controls.
• Pediatric labeling where applicable.

FDA labeling identifies specific inactive ingredients, but an ANDA applicant generally does not need to use the same supplier or identical manufacturing process. The applicant must demonstrate that its formulation meets the relevant quality and bioequivalence standards.

What licensing opportunities exist around LIALDA technology?

The main licensing opportunity is not the mesalamine molecule. It is the controlled-release platform and associated manufacturing know-how.

MMX technology has been associated with Cosmo Pharmaceuticals and has been used in mesalamine products developed through licensing and commercial partnerships. Platform owners may license:

• Matrix-formulation technology.
• Enteric-coating systems.
• Process parameters.
• Dissolution methods.
• Manufacturing scale-up packages.
• Regional commercialization rights.

Excipient suppliers can also pursue preferred-supplier agreements with formulation developers. These agreements may include technical-transfer support, minimum-volume commitments, change-control restrictions, and regulatory filing assistance.

No separate excipient-specific exclusivity is created merely by using a particular commercial grade. The business value depends on qualification, reproducibility, and integration into the customer's regulatory file.

How strong is the LIALDA patent estate?

The patent estate is materially weaker against generic competition once core formulation patents expire or are narrowed through litigation. Its remaining practical strength depends on claim scope, Orange Book listings, terminal disclaimers, pediatric extensions, and the ability to enforce process or formulation claims against specific products.

The active ingredient provides little barrier. The formulation platform provides the principal barrier. Manufacturing know-how can remain commercially useful after patent expiration because generic developers still need to reproduce the release profile at acceptable cost.

Key Takeaways

• LIALDA is a 1.2 g mesalamine delayed-release tablet using MMX matrix technology.
• The most important excipients are methacrylic acid copolymers, glyceryl behenate, carboxymethylcellulose sodium, and sodium starch glycolate.
• Excipient substitution can materially affect dissolution, tablet mechanics, coating integrity, and bioequivalence.
• Generic competition is the primary commercial threat; biosimilar risk does not apply.
• The strongest supplier opportunities are enteric-polymer systems, lipid matrix excipients, controlled-viscosity polymers, and regulatory-grade coating packages.
• Lactose-free, smaller-tablet, and alternative dosage-form products offer differentiated opportunities but may require more than a conventional ANDA strategy.
• MMX formulation and manufacturing know-how remain commercially relevant after active-ingredient patent expiry.
• Current Orange Book listings and litigation records should control any launch-date or patent-risk decision.

FAQs

Can LIALDA be reformulated without lactose?

Yes. Lactose can be replaced with another pharmaceutical filler, but the substitution may change compression, porosity, hydration, coating adhesion, dissolution, and bioequivalence.

Which excipient has the greatest effect on LIALDA release?

The enteric methacrylic acid copolymers and the glyceryl behenate-cellulose matrix are the most likely to have the largest effect on staged release behavior.

Is a mesalamine generic a biosimilar?

No. Mesalamine is a chemically synthesized small molecule. Generic mesalamine products are approved through the ANDA pathway.

Can an excipient supplier obtain exclusivity for LIALDA-grade material?

An excipient supplier can obtain a commercial supply agreement or preferred-source position, but use of a particular excipient grade does not itself create regulatory exclusivity.

Is LIALDA's once-daily dosing protected by excipient technology?

Once-daily dosing depends on the overall dosage-form design, including drug loading, matrix composition, coating, and release profile. Protection may arise from formulation or method-of-use claims, subject to the scope and status of the applicable patents.

References

1. Takeda Pharmaceuticals U.S.A., Inc. (2024). Lialda (mesalamine) delayed-release tablets: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. Cosmo Pharmaceuticals N.V. (2024). MMX technology and pharmaceutical delivery platforms. Company materials.